Arrowhead Pharmaceuticals, Inc. (ARWR)

US — Healthcare Sector

Peers: PRQR ALNY WVE BPMC APLS FOLD ACAD AXSM

Automate Your Wheel Strategy on ARWR

With Tiblio's Option Bot, you can configure your own wheel strategy including ARWR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol ARWR
Rev/Share 4.0882
Book/Share 5.1305
PB 3.0837
Debt/Equity 0.5682
CurrentRatio 5.1474
ROIC -0.0845

MktCap 2181980000.0
FreeCF/Share 0.072
PFCF 227.3843
PE -14.636
Debt/Assets 0.2467
DivYield 0
ROE -0.46

Rating C-
Score 1
Recommendation Strong Sell
P/E Score 1
DCF Score 1
P/B Score 3
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

ARWR, SRPT
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Negative

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price due to concerns over milestone payments and clinical program continuity. Arrowhead's financial position remains strong, even with a reduced runway caused by the lack of promised milestone payments from Sarepta. In today's article, I discuss a range of potential outcomes for the collaboration between Sarepta Therapeutics and Arrowhead Pharmaceuticals and what Arrowhead can do with its pipeline and financials.

image for news How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

ARWR
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company's global Phase 3 clinical studies designed to support regulatory submissions for marketing approval of investigational plozasiran in the treatment of severe hypertriglyceridemia. Arrowhead anticipates completing the primary portion of these studies in mid-2026 with topline data expected shortly thereafter and planned su.

image for news Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

ARWR
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: BofA Securities 2025 Health Care Conference – May 13-15, 2025 Type: Fireside Chat Presentation Date/Time: May 14, 2025, 11:20 a.m. PDT 2025 RBC Capital Markets Global Healthcare – May 20-21, 2025 Type: Fireside Chat Presentation Date/Time: May 20, 2025, 2:35 p.m. EDT Presentation webcasts may be accessed on the Events an.

image for news Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

ARWR
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Positive

Arrowhead Pharmaceuticals is executing on the clinical and regulatory side during adverse market conditions for biotech companies and genetic stocks in particular. Zodasiran is back in the clinic with a phase 3 trial plan in homozygous familiar hypercholesterolemia patients. We could see as many as three phase 1/2 readouts this year from programs that were recently partnered with Sarepta, and ARO-DM1 program milestones point to registrational intent.

image for news Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript

ARWR
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardio/Metabolic Franchise James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Luca Issi - RBC Capital David Lebowitz - Citi Jasmine Fels - UBS Maury Raycroft - Jefferies Edward Tenthoff - PSC Patrick Trucchio - H.C. Wainwright Mayank Mamtani - B.

image for news Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript

About Arrowhead Pharmaceuticals, Inc. (ARWR)

IPO Date 1993-12-16
Website https://arrowheadpharma.com
Industry Biotechnology
CEO Christopher R. Anzalone
Employees 609

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.